MedTrace Logo

Effect of Rosiglitazone

NCT00285142 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-06-10

No results posted yet for this study

Summary

To evaluate :

* acute effects of a single dose of 8 mg rosiglitazone (therapeutic dose)
* on insulin secretion and
* insulin sensitivity in 12 healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

rosiglitazone

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • PIERRE PETIT, MD-PhD · Centre d'Investigation Clinique

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-06-30
Completion
2004-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285142 on ClinicalTrials.gov